In this area you will be able to:
- Propose, vote on, and discuss research ideas
- View current studies
- View published research
Here, you can submit a research idea to the community, cast your votes, and discuss research ideas proposed by other members. Please make your research question as specific as possible. Other members will vote on your research idea, and we will prioritize research ideas with the most votes.
You are allowed to vote for your own proposed research idea if you want. However, you can only vote for a total of five research ideas. If you have already cast your five votes and an idea you like even more is proposed, you can change your votes at any time to reflect your current preferences.
The research team will review all submitted ideas and provide a response to you and to the community. If your idea leads to an IBD Partners Study, you will have the opportunity to serve as a patient collaborator on the research team for that study.
We encourage you to prioritize the ideas that are most important to you, even if the research team determines that your idea is not a good fit for IBD Partners. We will share ideas labeled “Not a Good Fit” with researchers outside of our network when appropriate. We want to make sure all of your votes count!
Thanks for your participation in this important platform to help the IBD research community understand what research questions are important to patients. We are passionate about finding answers to your questions!
For those patients who have failed anti-TNF alpha therapy, what is the next best step? Is Entyvio, Stelara, or Xeljanz more effective?
Many patients, myself included, have either not responded to anti-TNF therapies or have lost response. It would be helpful for both doctors and patients to know what the next best step is.
IBD can have a significant impact on motility and gut absorption. Most medication pharmacokinetic studies are completed using healthy volunteers. If there is a significant impact on oral medication absorption/pharmacokinetics with active IBD, this may have an important role in determining a safe and effective dose.
CBDs seen to be a readily available and benign treatment for inflammation of many types. They may prove to be a treatment much easier on the body than the current course of drugs.
I take it now on the advice of my functional medicine doctor, and think it helps me...
As this is a drug being regularly used and although not relatively new, the known long term side effects are not widely known
Create a database that tracks the long-term outcomes for patients on biologic medications (Remicade, Humira, Cimzia, Simponi, Tysabri, and Entyvio) to assess their long-term efficacy.
As IBD research and treatments progress, biologics are becoming an ever-more staple part of a patients treatment regimen. However, many patients still fail to respond effectively to these medications while others can maintain long-term remission specifically because of them. I believe it is important for the IBD community to further explore why this variation in response occurs, and tracking those that respond effectively to these biologic drugs can, perhaps, help us to better understand why some respond while others do not.
Multiple doctors have recommended that I start treatment for my Crohn's disease. There are many options from diet change, steroids, and immonosuapresants. My CD is very active and I have already had two surgeries.
How many IBD patients take antidepressants to help manage their health? Does this help to fight off remission by controlling depression?
Anything that prevents remission is important!
Diarrhea is a big problem in IBD, and it can be caused by many different factors. I was wondering if we might help each other by discovering what everyone uses and how well it works.
Not every patient is aware of options for controlling this distressing symptom
Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome (IBD-IBS) on patient reported outcomes in CCFA Partners
Variation in Care of Inflammatory Bowel Diseases Patients in CCFA Partners: Role of Gastroenterologist Practice Setting in Disease Outcomes and Quality Process Measures